DZ2891A1 - Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number: DZ2891A1
Authority: DZ; Algeria
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; new substituted; tetrahydroquinoline derivatives
Prior art date: 1998-09-17

Application number

DZ990191A

Other languages

English (en)

Inventor

Michael Paul Deninno

George Tetteh

Magnus Aryitey

Roger Benjamin Ruggeri

Ronald Thure Wester

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2003-12-15

1999-09-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2891A1 publication Critical patent/DZ2891A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DZ990191A 1998-09-17 1999-09-13 Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2891A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10092798P	1998-09-17	1998-09-17

Publications (1)

Publication Number	Publication Date
DZ2891A1 true DZ2891A1 (fr)	2003-12-15

Family

ID=22282246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990191A DZ2891A1 (fr)	1998-09-17	1999-09-13	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (50)

Country	Link
US (2)	US6140343A (fr)
EP (1)	EP1114032B1 (fr)
JP (1)	JP3561474B2 (fr)
KR (1)	KR100422286B1 (fr)
CN (2)	CN1318057A (fr)
AP (1)	AP1345A (fr)
AR (1)	AR030523A1 (fr)
AT (1)	ATE268324T1 (fr)
AU (1)	AU747715B2 (fr)
BG (1)	BG65101B1 (fr)
BR (1)	BR9913855A (fr)
CA (1)	CA2344248C (fr)
CO (1)	CO5290250A1 (fr)
CR (1)	CR6306A (fr)
CU (1)	CU23053A3 (fr)
CZ (1)	CZ2001954A3 (fr)
DE (1)	DE69917790T2 (fr)
DK (1)	DK1114032T3 (fr)
DZ (1)	DZ2891A1 (fr)
EA (1)	EA005761B1 (fr)
EE (1)	EE200100167A (fr)
ES (1)	ES2221420T3 (fr)
GC (1)	GC0000108A (fr)
GE (1)	GEP20032973B (fr)
GT (1)	GT199900147A (fr)
HK (1)	HK1039938A1 (fr)
HR (1)	HRP20010200B1 (fr)
HU (1)	HUP0103512A3 (fr)
ID (1)	ID27838A (fr)
IL (1)	IL141388A0 (fr)
IS (1)	IS2278B (fr)
MA (1)	MA26689A1 (fr)
MY (1)	MY121405A (fr)
NO (1)	NO319781B1 (fr)
NZ (1)	NZ509837A (fr)
OA (1)	OA11651A (fr)
PA (1)	PA8481201A1 (fr)
PE (1)	PE20001054A1 (fr)
PL (1)	PL198124B1 (fr)
PT (1)	PT1114032E (fr)
SI (1)	SI1114032T1 (fr)
SK (1)	SK3532001A3 (fr)
SV (1)	SV1999000150A (fr)
TN (1)	TNSN99170A1 (fr)
TR (1)	TR200100780T2 (fr)
TW (1)	TW502022B (fr)
UA (1)	UA70960C2 (fr)
WO (1)	WO2000017165A1 (fr)
YU (1)	YU18101A (fr)
ZA (1)	ZA200101745B (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US7115279B2 (en)	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) *	2001-01-26	2006-12-21	Schering Corporation	Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv)	2001-03-30	2001-03-30	Astrazeneca Ab	New compounds
US20030064967A1 (en) *	2001-04-11	2003-04-03	Jayraz Luchoomun	Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
ES2256461T3 (es) *	2001-04-30	2006-07-16	Pfizer Products Inc.	Compuestos utiles como intermediarios de derivados de 4-aminoquinolina.
TNSN03139A1 (fr) *	2001-06-21	2005-12-23	Pfizer Prod Inc	Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
MXPA03011784A (es)	2001-06-22	2004-04-02	Pfizer Prod Inc	Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
EP1269994A3 (fr)	2001-06-22	2003-02-12	Pfizer Products Inc.	Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
JP4547148B2 (ja)	2001-06-22	2010-09-22	ベンド・リサーチ・インコーポレーテッド	非晶質薬剤の吸着物の医薬組成物
IL162533A0 (en) *	2001-12-19	2005-11-20	Atherogenics Inc	Chalcone derivatives and their use to treat diseases
WO2003053359A2 (fr)	2001-12-19	2003-07-03	Atherogenics, Inc.	1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
WO2003055482A1 (fr) *	2001-12-21	2003-07-10	Novo Nordisk A/S	Derives amide utiles en tant qu'activateurs de la glucokinase
AR038375A1 (es)	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
KR100664822B1 (ko) *	2002-02-01	2007-01-04	화이자 프로덕츠 인코포레이티드	변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
PL371416A1 (en) *	2002-02-01	2005-06-13	Pfizer Products Inc.	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
WO2003063833A1 (fr)	2002-02-01	2003-08-07	Pfizer Products Inc.	Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
AU2003243921B2 (en) *	2002-06-27	2009-05-07	Novo Nordisk A/S	Aryl carbonyl derivatives as therapeutic agents
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20090181966A1 (en) *	2002-10-04	2009-07-16	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en)	2002-10-04	2005-12-27	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en)	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
CA2500083A1 (fr) *	2002-10-21	2004-04-29	Warner-Lambert Company Llc	Derives de tetrahydroquinoline antagonistes de crth2
WO2004052863A1 (fr) *	2002-12-06	2004-06-24	Kyowa Hakko Kogyo Co., Ltd.	Anti-inflammatoire
WO2004056727A2 (fr) *	2002-12-19	2004-07-08	Atherogenics, Inc.	Procede de fabrication de derives de chalcone
EP1961419B1 (fr)	2002-12-20	2010-03-24	Pfizer Products Inc.	Formes posologiques comprenant un inhibiteur de CETP et un inhibiteur de HMG-CoA reductase
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1435356A1 (fr) *	2003-01-06	2004-07-07	Warner-Lambert Company LLC	Dérivés de la quinoléine en tant qu'antagonistes de CRTH2
WO2004072042A2 (fr) *	2003-02-12	2004-08-26	Carex S.A.	Modulation de l'activite de recepteurs nucleaires
AU2004222436A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
PT1603553E (pt)	2003-03-17	2012-02-03	Japan Tobacco Inc	Composições farmacêuticas de inibidores de cetp
US20040204450A1 (en) *	2003-03-28	2004-10-14	Pfizer Inc	Quinoline and quinoxaline compounds
CN1795177A (zh) *	2003-03-28	2006-06-28	辉瑞产品公司	作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CN1812983A (zh)	2003-05-30	2006-08-02	兰贝克赛实验室有限公司	取代的吡咯衍生物及其作为hmg－co抑制剂的用途
MXPA06001417A (es)	2003-08-04	2006-05-15	Pfizer Prod Inc	Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
RU2330682C2 (ru)	2003-09-26	2008-08-10	Джапан Тобакко Инк.	Способ ингибирования продуцирования остаточных липопротеинов
EP1670765A2 (fr) *	2003-09-30	2006-06-21	Pfizer Products Inc.	Inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp) et leurs metabolites
PL1670768T3 (pl) *	2003-10-08	2010-01-29	Lilly Co Eli	Związki i sposoby leczenia dyslipidemii
US7390504B2 (en) *	2003-11-07	2008-06-24	Jj Pharma, Inc.	HDL-boosting combination therapy complexes
PT1723128E (pt) *	2004-01-06	2013-02-27	Novo Nordisk As	Heteroaril-ureias e o seu uso como activadores da glicoquinase
NZ549721A (en)	2004-03-05	2010-08-27	Univ Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
EA200601785A1 (ru)	2004-03-26	2007-02-27	Эли Лилли Энд Компани	Соединения и способы лечения дислипидемии
UA90269C2 (ru)	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
MY139887A (en)	2004-04-02	2009-11-30	Mitsubishi Tanabe Pharma Corp	Tetrahydronaphthyridine derivatives and a process for preparing the same.
WO2006009819A1 (fr) *	2004-06-18	2006-01-26	Array Biopharma Inc.	Inhibiteurs de proteines de transfert d'ester de cholesteryle
JP2008504266A (ja) *	2004-06-24	2008-02-14	イーライリリーアンドカンパニー	異脂肪血症を治療するための化合物及び方法
KR100859223B1 (ko) *	2004-06-24	2008-09-18	일라이 릴리 앤드 캄파니	이상지혈증 치료를 위한 화합물 및 방법
WO2006004903A2 (fr) *	2004-06-28	2006-01-12	Atherogenics, Inc.	1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es)	2004-07-02	2011-07-15	Merck Sharp & Dohme	Inhibidores de cetp
CN104958270A (zh) *	2004-08-25	2015-10-07	伊森舍丽斯有限公司	钾atp通道开放剂的药物制剂及其应用
US20060063803A1 (en) *	2004-09-23	2006-03-23	Pfizer Inc	4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US20070149567A1 (en) *	2004-09-23	2007-06-28	Pfizer Inc	Quinoline compounds
AU2005308575A1 (en) *	2004-11-23	2006-06-01	Warner-Lambert Company Llc	7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006069162A1 (fr) *	2004-12-20	2006-06-29	Reddy Us Therapeutics, Inc.	Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
DK1848430T3 (da)	2004-12-31	2017-11-06	Dr Reddys Laboratories Ltd	Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP2548894A1 (fr)	2005-02-03	2013-01-23	Bend Research, Inc.	Compositions pharmaceutiques à éfficacité améliorée
BRPI0608553A2 (pt)	2005-02-24	2010-01-12	Millennium Pharm Inc	antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
WO2006098394A1 (fr) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
EP1901741B1 (fr) *	2005-07-01	2015-09-16	Merck Sharp & Dohme Corp.	Procede permettant d'effectuer la synthese d'un inhibiteur de cetp
JP2009500378A (ja) *	2005-07-08	2009-01-08	ノボ・ノルデイスク・エー／エス	グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
KR20080024211A (ko) *	2005-07-08	2008-03-17	노보 노르디스크 에이/에스	디시클로알킬 우레아 글루코키나제 활성제
BRPI0612996A2 (pt) *	2005-07-14	2010-12-14	Novo Nordisk As	ativadores de urÉia glucocinase
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
JP4681526B2 (ja) *	2005-09-29	2011-05-11	田辺三菱製薬株式会社	医薬組成物
JP4531027B2 (ja) *	2005-09-29	2010-08-25	田辺三菱製薬株式会社	医薬組成物
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
SG166829A1 (en)	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
PL1968601T3 (pl)	2006-01-05	2012-03-30	Essentialis Inc	Sole związków otwierających kanały potasowe ATP i ich zastosowanie
UY30118A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compueto amina trisustituido
UY30117A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
TW200808731A (en) *	2006-03-30	2008-02-16	Tanabe Seiyaku Co	A process for preparing tetrahydroquinoline derivatives
GB0615670D0 (en) *	2006-08-07	2006-09-13	Syngenta Participations Ag	Chemical compounds
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
CL2007002958A1 (es) *	2006-10-12	2008-05-09	Epix Delaware Inc	Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
JP5498168B2 (ja)	2006-12-01	2014-05-21	ブリストル−マイヤーズスクイブカンパニー	アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US20080161279A1 (en) *	2006-12-21	2008-07-03	Wisler Gerald L	Methods of Treating Obesity
US8138185B2 (en) *	2007-01-09	2012-03-20	Novo Nordisk A/S	Urea glucokinase activators
AU2008204530B2 (en) *	2007-01-11	2013-08-01	Vtv Therapeutics Llc	Urea glucokinase activators
CN101220021B (zh) *	2007-01-12	2010-12-08	上海医药工业研究院	4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
MX2009010962A (es)	2007-04-13	2009-12-16	Kowa Co	Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
JP2010532383A (ja) *	2007-07-02	2010-10-07	エッセンシャリス，インク．	カリウムａｔｐチャネル開口薬の塩およびその使用
AR069165A1 (es)	2007-11-05	2010-01-06	Novartis Ag	Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
PT2404901E (pt)	2007-12-03	2013-08-29	Novartis Ag	Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como a hiperlipidemia ou a arteriosclerose
KR20100102646A (ko)	2007-12-11	2010-09-24	가부시키가이샤 사이토파스파인더	카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
JP5654572B2 (ja)	2009-05-15	2015-01-14	ノバルティスアーゲー	アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体
BRPI1010600A2 (pt)	2009-05-15	2016-03-15	Novartis Ag	aril piridina como inibidores de aldosterona sintase
SG176010A1 (en)	2009-05-28	2011-12-29	Novartis Ag	Substituted aminobutyric derivatives as neprilysin inhibitors
JP5420761B2 (ja)	2009-05-28	2014-02-19	ノバルティスアーゲー	ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
TWI450896B (zh) *	2009-06-30	2014-09-01	Lilly Co Eli	反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
ES2663351T3 (es)	2009-11-17	2018-04-12	Novartis Ag	Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en)	2009-11-30	2013-11-05	Novartis Ag	Imidazole derivatives as aldosterone synthase inhibitors
CA2799708A1 (fr)	2010-05-21	2011-11-24	Pfizer Inc.	2-phenylbenzoylamides
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
EP2668507B1 (fr)	2011-01-26	2017-08-23	INSERM - Institut National de la Santé et de la Recherche Médicale	Méthode d'évaluation du risque d'un sujet de contracter une maladie cardiovasculaire
CA2828343A1 (fr)	2011-03-04	2012-09-13	The Scripps Research Institute	Peptides de type edn3 et utilisations associees
JP5629403B2 (ja)	2011-06-17	2014-11-19	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｃｒｔｈ２受容体モジュレータとしてのシクロアルキル縮合テトラヒドロキノリン
AR087451A1 (es) *	2011-08-17	2014-03-26	Lilly Co Eli	Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
CA2845284C (fr)	2011-08-18	2018-03-06	Dr. Reddy's Laboratories Ltd.	Composes amines heterocycliques substitues comme inhibiteurs de la proteine de transfert d'ester cholesterylique (cetp)
JP6140168B2 (ja)	2011-09-27	2017-05-31	ドクターレディズラボラトリーズリミテッド	アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
MX347400B (es)	2012-06-29	2017-04-18	Univ Nac Autónoma De México	Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
NZ710574A (en)	2013-02-14	2017-11-24	Novartis Ag	Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
SG11201507496UA (en)	2013-04-17	2015-11-27	Pfizer	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US9266925B2 (en)	2013-07-25	2016-02-23	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
BR112016001376A2 (pt)	2013-07-25	2017-10-24	Novartis Ag	bioconjugados de polipeptídeos de apelin sintéticos
EP3185869A1 (fr) *	2014-08-28	2017-07-05	Dezima Pharma B.V.	Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase
EP3186242B1 (fr)	2014-08-29	2021-10-06	Tes Pharma S.r.l.	Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
CA2972871A1 (fr)	2015-01-23	2016-07-28	Novartis Ag	Conjugues d'acides gras de l'apeline synthetique presentant une demi-vie amelioree
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AU2019287437A1 (en)	2018-06-12	2020-09-10	Vtv Therapeutics Llc	Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US11248001B2 (en)	2019-01-18	2022-02-15	Astrazeneca Ab	PCSK9 inhibitors and methods of use thereof
WO2021167840A1 (fr)	2020-02-18	2021-08-26	Vtv Therapeutics Llc	Activateurs de glucokinase sulfone et sulfoxyde et leurs procédés d'utilisation
CN116194442A (zh)	2020-06-08	2023-05-30	维特卫治疗有限责任公司	{2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途
EP4188372A1 (fr)	2020-07-29	2023-06-07	Amryt Pharmaceuticals Inc.	Lomitapide destiné à être utilisé dans des méthodes de traitement de l'hyperlipidémie et de l'hypercholestérolémie chez des patients pédiatriques
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en)	2023-05-24	2024-11-28	Novartis Ag	Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231102A (en) *	1989-03-08	1993-07-27	Merck Sharp & Dohme, Ltd.	Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) *	1990-06-18	1994-01-04	E. R. Squibb & Sons, Inc.	Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en)	1990-11-26	1995-03-28	E. R. Squibb & Sons, Inc.	Indane and quinoline derivatives
JPH0676403B2 (ja) *	1991-01-18	1994-09-28	エスエス製薬株式会社	新規なベンゾ［５，６シクロヘプタ［１，２−ｂピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en) *	1992-10-15	1994-02-22	Merck & Co., Inc.	Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en) *	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
US6147089A (en)	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
AU2157400A (en)	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications

1999
- 1999-09-06 GT GT199900147A patent/GT199900147A/es unknown
- 1999-09-07 US US09/391,313 patent/US6140343A/en not_active Expired - Fee Related
- 1999-09-08 GC GCP1999273 patent/GC0000108A/xx active
- 1999-09-08 PA PA19998481201A patent/PA8481201A1/es unknown
- 1999-09-10 TR TR2001/00780T patent/TR200100780T2/xx unknown
- 1999-09-10 YU YU18101A patent/YU18101A/sh unknown
- 1999-09-10 CN CN99811014A patent/CN1318057A/zh active Pending
- 1999-09-10 MY MYPI99003926A patent/MY121405A/en unknown
- 1999-09-10 CN CNA2004100049599A patent/CN1515259A/zh active Pending
- 1999-09-10 CZ CZ2001954A patent/CZ2001954A3/cs unknown
- 1999-09-10 AT AT99940426T patent/ATE268324T1/de not_active IP Right Cessation
- 1999-09-10 GE GEAP19995804A patent/GEP20032973B/en unknown
- 1999-09-10 AP APAP/P/2001/002100A patent/AP1345A/en active
- 1999-09-10 SK SK353-2001A patent/SK3532001A3/sk unknown
- 1999-09-10 CA CA002344248A patent/CA2344248C/fr not_active Expired - Fee Related
- 1999-09-10 PE PE1999000922A patent/PE20001054A1/es not_active Application Discontinuation
- 1999-09-10 TW TW088115688A patent/TW502022B/zh not_active IP Right Cessation
- 1999-09-10 SI SI9930595T patent/SI1114032T1/xx unknown
- 1999-09-10 HU HU0103512A patent/HUP0103512A3/hu unknown
- 1999-09-10 UA UA2001031791A patent/UA70960C2/uk unknown
- 1999-09-10 BR BR9913855-7A patent/BR9913855A/pt not_active Application Discontinuation
- 1999-09-10 AU AU54403/99A patent/AU747715B2/en not_active Ceased
- 1999-09-10 ID IDW20010621A patent/ID27838A/id unknown
- 1999-09-10 IL IL14138899A patent/IL141388A0/xx not_active IP Right Cessation
- 1999-09-10 ES ES99940426T patent/ES2221420T3/es not_active Expired - Lifetime
- 1999-09-10 DK DK99940426T patent/DK1114032T3/da active
- 1999-09-10 JP JP2000574075A patent/JP3561474B2/ja not_active Expired - Fee Related
- 1999-09-10 AR ARP990104554A patent/AR030523A1/es active IP Right Grant
- 1999-09-10 SV SV1999000150A patent/SV1999000150A/es not_active Application Discontinuation
- 1999-09-10 HK HK02101447.5A patent/HK1039938A1/zh unknown
- 1999-09-10 CO CO99057641A patent/CO5290250A1/es not_active Application Discontinuation
- 1999-09-10 DE DE69917790T patent/DE69917790T2/de not_active Expired - Fee Related
- 1999-09-10 PL PL346830A patent/PL198124B1/pl not_active IP Right Cessation
- 1999-09-10 NZ NZ509837A patent/NZ509837A/xx unknown
- 1999-09-10 PT PT99940426T patent/PT1114032E/pt unknown
- 1999-09-10 OA OA1200100062A patent/OA11651A/en unknown
- 1999-09-10 EP EP99940426A patent/EP1114032B1/fr not_active Expired - Lifetime
- 1999-09-10 EE EEP200100167A patent/EE200100167A/xx unknown
- 1999-09-10 CU CU20010051A patent/CU23053A3/es unknown
- 1999-09-10 KR KR10-2001-7003416A patent/KR100422286B1/ko not_active Expired - Fee Related
- 1999-09-10 HR HR20010200A patent/HRP20010200B1/xx not_active IP Right Cessation
- 1999-09-10 WO PCT/IB1999/001534 patent/WO2000017165A1/fr not_active Ceased
- 1999-09-10 EA EA200100249A patent/EA005761B1/ru not_active IP Right Cessation
- 1999-09-13 MA MA25766A patent/MA26689A1/fr unknown
- 1999-09-13 TN TNTNSN99170A patent/TNSN99170A1/fr unknown
- 1999-09-13 DZ DZ990191A patent/DZ2891A1/fr active
2000
- 2000-09-27 US US09/671,221 patent/US6489478B1/en not_active Expired - Fee Related
2001
- 2001-02-14 CR CR6306A patent/CR6306A/es unknown
- 2001-02-23 IS IS5858A patent/IS2278B/is unknown
- 2001-03-01 ZA ZA200101745A patent/ZA200101745B/en unknown
- 2001-03-16 NO NO20011349A patent/NO319781B1/no not_active IP Right Cessation
- 2001-04-10 BG BG105429A patent/BG65101B1/bg unknown

Also Published As

Publication number	Publication date
EP1114032B1 (fr)	2004-06-02
UA70960C2 (uk)	2004-11-15
BG105429A (en)	2001-12-29
HRP20010200A2 (en)	2002-04-30
GEP20032973B (en)	2003-05-27
CA2344248A1 (fr)	2000-03-30
HUP0103512A3 (en)	2002-03-28
DE69917790D1 (de)	2004-07-08
NZ509837A (en)	2002-11-26
PT1114032E (pt)	2004-09-30
GT199900147A (es)	1999-09-06
DK1114032T3 (da)	2004-08-16
ES2221420T3 (es)	2004-12-16
PA8481201A1 (es)	2000-09-29
CR6306A (es)	2003-08-28
YU18101A (sh)	2004-05-12
BR9913855A (pt)	2001-07-24
US6140343A (en)	2000-10-31
AU747715B2 (en)	2002-05-23
KR20010085814A (ko)	2001-09-07
KR100422286B1 (ko)	2004-03-11
CU23053A3 (es)	2005-06-24
SK3532001A3 (en)	2001-12-03
TNSN99170A1 (fr)	2005-11-10
CA2344248C (fr)	2007-01-09
EE200100167A (et)	2002-06-17
CO5290250A1 (es)	2003-06-27
SV1999000150A (es)	2000-06-06
AR030523A1 (es)	2003-08-27
AU5440399A (en)	2000-04-10
TW502022B (en)	2002-09-11
IL141388A0 (en)	2002-03-10
MY121405A (en)	2006-01-28
ATE268324T1 (de)	2004-06-15
WO2000017165A1 (fr)	2000-03-30
EA200100249A1 (ru)	2001-08-27
NO20011349L (no)	2001-05-14
MA26689A1 (fr)	2004-12-20
HK1039938A1 (zh)	2002-05-17
HRP20010200B1 (en)	2006-10-31
DE69917790T2 (de)	2005-06-09
ZA200101745B (en)	2002-05-02
HUP0103512A2 (hu)	2002-02-28
IS2278B (is)	2007-09-15
NO20011349D0 (no)	2001-03-16
SI1114032T1 (fr)	2004-12-31
CN1318057A (zh)	2001-10-17
ID27838A (id)	2001-04-26
NO319781B1 (no)	2005-09-12
US6489478B1 (en)	2002-12-03
PL346830A1 (en)	2002-02-25
CZ2001954A3 (cs)	2001-12-12
JP3561474B2 (ja)	2004-09-02
PL198124B1 (pl)	2008-05-30
EA005761B1 (ru)	2005-06-30
TR200100780T2 (tr)	2001-07-23
JP2002526476A (ja)	2002-08-20
AP1345A (en)	2004-12-15
AP2001002100A0 (en)	2001-03-31
PE20001054A1 (es)	2000-10-14
OA11651A (en)	2004-12-07
BG65101B1 (bg)	2007-02-28
GC0000108A (en)	2005-06-29
IS5858A (is)	2001-02-23
EP1114032A1 (fr)	2001-07-11
CN1515259A (zh)	2004-07-28

Publication	Publication Date	Title
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr)	2004-03-27	Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2227A1 (fr)	2002-12-25	Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ2880A1 (fr)	2003-12-15	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.
DZ2457A1 (fr)	2004-11-08	Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.